UBS analyst Matthew Taylor upgraded Tandem Diabetes Care to Buy from Neutral with an unchanged price target of $75. The stock closed Thursday up $1.53 to $56.58. The analyst says that while he understands concerns about slowing growth on tough comps, he sees "several sources of growth" that should allow Tandem to deliver upside to consensus in 2020 and beyond. The stock offers 33% upside from current levels and a favorable risk/reward skew, Taylor tells investors in a research note. While Tandem will derive less revenue from Animas patients next year, the gap can be more than filled by pump market growth that is accelerating, market share gains of new patients, and the company's "underpenetrated" growth outside the U.S., contends the analyst.